Skip to main content
. 2013 May 1;4(5):705–714. doi: 10.18632/oncotarget.974

Figure 1a and b. Kaplan Meier curve showing PFS on best standard systemic treatment in patients with mtp53 comparing bevacizumab (n = 22) vs. non-bevacizumab containing regimens (n = 35).

Figure 1a and b

Kaplan Meier curve showing PFS on best standard systemic treatment in wtp53 comparing bevacizumab (n = 7) vs. non-bevacizumab containing regimens (n = 48).